ClinicalTrials.gg
RecruitingNCT06366412Updated Apr 15, 2024

Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.

A Phase 4 interventional study of Dexmedetomidine Hydrochloride and normal saline in Cognitive Impairment, sponsored by Minia University Hospital. Recruiting at 1 site in Egypt. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Minia University Hospital · Phase 4, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing dexmedetomidine in Cognitive Dysfunction — 3 open to participants now, 5 under way, none of them phase 3. Dexmedetomidine · Cognitive Dysfunction.

Planned enrollment
6th of 13
94 · median 90
Started
2024
with 1 other
Phase 4
7 of 13
3 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Minia University Hospital

Among the 13 studies testing dexmedetomidine in Cognitive Dysfunction, this one is the 6th largest by planned enrollment, is one of 2 that started in 2024, is one of 7 in phase 4, and was the 10th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

3 of the 13 studies testing dexmedetomidine in Cognitive Dysfunction are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing dexmedetomidine in Cognitive Dysfunction, or all of them as a file.
02

Study summary

To assess the effect of Dexmedetomidine on serum Tau-217 protein and its relation to the incidence and severity of postoperative cognitive dysfunction in elderly patients undergoing major surgery under general anesthesia.

Read the detailed description

to assess the effect of dexmedetomidine on serum Tau-217 protein through measuring serum Tau-217 protein preoperative and postoperative period and comparing the 2 measurements , assessing the cognitive dysfunction in the elderly patients and comparing the correlation between the cognitive dysfunction with serum tau-217 level also assessing the neuroprotective effect of dexmedetomidine on postoperative cognitive dysfunction and its relation with serum Tau-217 level.

03

Conditions studied

  • Cognitive Impairment

Keywords

  • dexmedetomidine
  • serum Tau-217 protein
  • cognitive dysfunction
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged > 65 years old, both genders, Basal Metabolic Index range 18.5 to less than 35 I - III with Glasgow Coma Scale 14-15 undergoing major surgery under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if they refused the enrollment in our study, Glasgow Coma Scale\<14 or if there is severe cardiac, liver or renal disease, patients have Alzehimer's Disease or any of the psychotic diseases, poorly educated patients and if there is any sensitivity to given drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine group

    Will receive induction of general anesthesia by loading dose of dexmedetomidine (Precedex) 0.6 μg/kg over 10 minutes in a 20 ml micropump, fentanyl in a dose of 1 μg /kg, propofol 1-1.5 mg/kg, and endotracheal intubation will be facilitated by 0.5mg/kg of atracurium and maintenance of anesthesia will be achieved by dexmedetomidine in a dose of 0.3 μg/kg/hr on 50 ml micropump and isoflurane (1-2%) in oxygen-air mixture.

    Drug: Dexmedetomidine Hydrochloride

  • Placebo comparator
    Placebo group

    Will receive induction of general anesthesia by infusion of normal saline 20 ml micropump over 10 min, fentanyl in a dose of 1 μg/kg, propofol 1-1.5 mg/kg and endotracheal intubation will be facilitated by 0.5mg/kg of atracurium and maintenance of anesthesia will be achieved by isoflurane (1-2%) in oxygen-air mixture and infusion of 50 ml/hr micropump of normal saline.

    Other: normal saline

Interventions

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.

    Also known as: precedex

  • Othernormal saline

    normal saline will be administrated in placebo group

06

What researchers measure

Primary outcomes

  1. the effect of dexmedetomidine on serum Tau-217 protein value.

    estimation of the effect of dexmedetomidine on serum Tau-217 protein in postoperative period.

    Time frame: 2 years

Secondary outcomes

  1. to evaluate the postoperative cognitive dysfunction using Mini-Mental State Scale in both the placebo and dexmedetomidine group.

    evaluation of the postoperative cognitive dysfunction by Mini Mental State Scale as \>25 is recorded normal while less than \<24 is positive for cognitive dysfunction.

    Time frame: 2 years

Other outcomes

  1. Heart Rate changes in the intraoperative period after induction of anesthesia and every 10 minutes till the end of surgery and postoperative period after 1 hour and every hour till 6 hours postoperative then every 6 hours

    Heart Rate will be measured in beat/min

    Time frame: 2 years

  2. Mean Arterial Blood Pressure changes in the intraoperative period after induction of anesthesia and every 10 minutes till the end of surgery and postoperative period after 1 hour and every hour till 6 hours postoperative then every 6 hours

    Mean Arterial Blood Pressure will be measured in mmHg/min

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Arwa Essam
    Minya, 61111, Egypt
    Recruiting
    • Arwa essam Essam, assistant lecturer · Contactarwty26@gmail.com · +201017565658
08

References and documents

Publications

  • Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H, VandeVrede L, Proctor NK, Lago AL, Baker S, Sivasankaran R, Kieloch A, Kinhikar A, Yu L, Valentin MA, Jeromin A, Zetterberg H, Hansson O, Mattsson-Carlgren N, Graham D, Blennow K, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Teunissen CE, Rabinovici GD, Rojas JC, Dage JL, Boxer AL; Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021 Sep;20(9):739-752. doi: 10.1016/S1474-4422(21)00214-3. Erratum In: Lancet Neurol. 2021 Oct;20(10):e6. doi: 10.1016/S1474-4422(21)00286-6. PubMed 34418401 ↗
  • McKay TB, Qu J, Liang F, Mueller A, Wiener-Kronish J, Xie Z, Akeju O. Tau as a serum biomarker of delirium after major cardiac surgery: a single centre case-control study. Br J Anaesth. 2022 Jul;129(1):e13-e16. doi: 10.1016/j.bja.2022.04.002. Epub 2022 Apr 22. No abstract available. PubMed 35465951 ↗
  • Ballweg T, White M, Parker M, Casey C, Bo A, Farahbakhsh Z, Kayser A, Blair A, Lindroth H, Pearce RA, Blennow K, Zetterberg H, Lennertz R, Sanders RD. Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. Br J Anaesth. 2021 Feb;126(2):458-466. doi: 10.1016/j.bja.2020.08.061. Epub 2020 Nov 20. PubMed 33228978 ↗
  • Liang F, Baldyga K, Quan Q, Khatri A, Choi S, Wiener-Kronish J, Akeju O, Westover MB, Cody K, Shen Y, Marcantonio ER, Xie Z. Preoperative Plasma Tau-PT217 and Tau-PT181 Are Associated With Postoperative Delirium. Ann Surg. 2023 Jun 1;277(6):e1232-e1238. doi: 10.1097/SLA.0000000000005487. Epub 2022 Jul 6. PubMed 35794069 ↗
  • Wang W, Ma Y, Liu Y, Wang P, Liu Y. Effects of Dexmedetomidine Anesthesia on Early Postoperative Cognitive Dysfunction in Elderly Patients. ACS Chem Neurosci. 2022 Aug 3;13(15):2309-2314. doi: 10.1021/acschemneuro.2c00173. Epub 2022 Jul 21. PubMed 35864562 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Mar 2025, 11 months later.

Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's planned 11 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 15, 2024
StartEst.
Apr 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2026
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06366412
Lead sponsor
Minia University Hospital
Responsible party
Arwa Essam (Assistant Lecturer, Minia University Hospital) — Principal investigator
First posted
Apr 15, 2024
Start date
Apr 2024 (estimated)
Primary completion
Mar 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Apr 15, 2024

Study contacts

Arwa Essam Anwar, Assistant Lecturer
Contact
arwty26@gmail.com
+201017565658
Amr Nady Abd Elrazik, Assistant Lecturer
Contact
+201023451177

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion